Targeting Angiogenesis in Head and Neck Cancer

Author(s): Nabil F. Saba, Dong M. Shin, Fadlo R. Khuri

Journal Name: Current Cancer Drug Targets

Volume 7 , Issue 7 , 2007

Become EABM
Become Reviewer
Call for Editor


In the early 1970s, the hypothesis that tumor growth is dependent on angiogenesis was first established [1]. Since then, the role played by blood vessels in tumor growth and progression has been extensively studied and debated. Preclinical evidence strongly suggests that VEGF plays a role in promoting the growth and progression of disease in various tumor types including squamous cell carcinoma of the head and neck (SCCHN), of which close to 38,500 new cases are diagnosed each year. In SCCHN, the role of antiangiogenic therapy has yet to be defined. Traditional therapy of SCCHN has involved a multimodality approach with radiotherapy, surgery as well as chemotherapy. More recently, novel therapeutic agents have been subject to preclinical and clinical development, among which anti-angiogenic therapy has gained much recent interest. In this critical review, we give an overview of angiogenesis and its potential therapeutic targets, and we focus on its preclinical and clinical applications in SCCHN.

Keywords: Angiogenesis, head and neck, endothelial, VEGF, targeted therapy, squamous cell carcinoma, endothelial growth factor, antiangiogenesis

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Page: [643 - 649]
Pages: 7
DOI: 10.2174/156800907782418356
Price: $65

Article Metrics

PDF: 1